open access

Vol 4, No 3 (2013)
Review paper
Published online: 2013-11-13
Get Citation

Effi cacy of primary myelofi brosis therapy with JAK2 inhibitors

Tomasz Sacha
Hematologia 2013;4(3):197-205.

open access

Vol 4, No 3 (2013)
REVIEW ARTICLES
Published online: 2013-11-13

Abstract

Primary myelofi brosis (PMF) is a Philadelphia (Ph) negative myeloproliferative neoplasm (MPN)characterized by symptoms derived from anemia and splenomegaly and constitutional symptomsand associated with a median survival of 5–7 years. The effi cacy of current conventional therapy of PMF is modest, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) is complicatedby relatively high treatment-related mortality and morbidity. The discovery of molecular mechanisms and role of JAK-STAT pathway dysregulation involved in the pathogenesis of MPN triggered the development of novel, targeted therapies. In this publication the results of PMF therapy with ruxolitinib, CYT378 and SAR302503 — three JAK2 inhibitors documented in phase-I, II and III trials are reported. By the incorporation of JAK2 inhibitors into current PMF therapy a profound symptomatic relief, and hopefully a certain improvement of treatment efficacy and survival prolongation can be achieved.

Abstract

Primary myelofi brosis (PMF) is a Philadelphia (Ph) negative myeloproliferative neoplasm (MPN)characterized by symptoms derived from anemia and splenomegaly and constitutional symptomsand associated with a median survival of 5–7 years. The effi cacy of current conventional therapy of PMF is modest, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) is complicatedby relatively high treatment-related mortality and morbidity. The discovery of molecular mechanisms and role of JAK-STAT pathway dysregulation involved in the pathogenesis of MPN triggered the development of novel, targeted therapies. In this publication the results of PMF therapy with ruxolitinib, CYT378 and SAR302503 — three JAK2 inhibitors documented in phase-I, II and III trials are reported. By the incorporation of JAK2 inhibitors into current PMF therapy a profound symptomatic relief, and hopefully a certain improvement of treatment efficacy and survival prolongation can be achieved.
Get Citation

Keywords

myelofi brosis, treatment, JAK-2, ruxolitinib

About this article
Title

Effi cacy of primary myelofi brosis therapy with JAK2 inhibitors

Journal

Hematology in Clinical Practice

Issue

Vol 4, No 3 (2013)

Article type

Review paper

Pages

197-205

Published online

2013-11-13

Bibliographic record

Hematologia 2013;4(3):197-205.

Keywords

myelofi brosis
treatment
JAK-2
ruxolitinib

Authors

Tomasz Sacha

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.